Clinical trials: Frown Lines
Glabellar Frown Lines
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
An interventional phase 2 study to evaluate safety and efficacy of AbobotulinumtoxinA treatment for glabellar lines
- Trial name
- NCT03736928
- Testing
- AbobotulinumtoxinA dose level 1 or 2, AbobotulinumtoxinA dose 3, AbobotulinumtoxinA dose 4
- Where
- 10 sites in United States
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Frown Lines
Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
The objective of this study is to evaluate the aesthetic improvement and onset of QM1114-DP treatment for subjects with moderate to severe glabellar lines
- Trial name
- NCT05146999
- Testing
- QM1114-DP
- Where
- 9 sites in United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Frown Lines
Efficacy and Safety Study of MT10107 in the Treatment of Glabella Line
This study design is a parallel, active drug controlled, double blind, randomized, multi-centered, phase III clinical trial to compare the efficacy and safety of MT10107 versus BOTOX® in treatment of glabella line.
- Trial name
- NCT03908008
- Testing
- Botox (Botulinum toxin type A), MT10107 (Botulinum toxin type A)
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Medy-Tox
Glabellar Frown Lines
A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001
The primary objective is to demonstrate the safety and efficacy of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in the treatment of moderate to severe glabellar lines associated with corrugator and/or procerus muscle…
- Trial name
- NCT02334423
- Testing
- Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
- Where
- United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Frown Lines
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I
The aim of this study is to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo, including efficacy after repeat treatments and long term safety.
- Trial name
- BLESS I (NCT02677298)
- Testing
- Botulinum Toxin A
- Where
- 18 sites in United States, Germany and 1 more
- Volunteers
- 784 people, healthy volunteers welcome
- Sponsor
- Croma-Pharma GmbH
Glabellar Frown Lines
Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines
An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines
- Trial name
- NCT03960957
- Testing
- AbobotulinumtoxinA
- Where
- 11 sites in United States
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Frown Lines
Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines
Efficacy and safety of the investigational product, ATGC-110, was evaluated in comparison with Xeomin for a total of 16 weeks after the administration in treatment of glabellar frown lines.
- Trial name
- NCT05623410
- Testing
- ATGC-110, Xeomin®
- Where
- South Korea
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- ATGC Co., Ltd.
Glabellar Frown Lines (GL)
Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines
To evaluate the safety and efficacy of EB-001 compared to placebo in subjects with glabellar frown lines (GL).
- Trial name
- NCT02939326
- Testing
- EB-001 injection
- Where
- 2 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Bonti, Inc.
Glabellar Frown Lines
A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002
The primary objective is to demonstrate the safety and efficacy of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in the treatment of moderate to severe glabellar lines associated with corrugator and/or procerus muscle…
- Trial name
- EV-002 (NCT02334436)
- Testing
- Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
- Where
- United States
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Frown Lines
A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines
Efficacy and safety of the investigational product, ATGC-110, was evaluated in comparison with Botox for a total of 12 weeks after the administration in treatment of glabellar frown lines.
- Trial name
- NCT04281095
- Testing
- Botulinum toxin type A
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- ATGC Co., Ltd.
Glabellar Frown Lines
The Safety and Efficacy Study of PROTOXIN in Subjects With Moderate to Severe Glabellar Lines
This study will be conducted in Phase I/II clinical trials. In Phase I, subjects with moderate to severe glabellar lines are enrolled and those who are judged to be eligible for this study will be injected with the "PROTOXIN" at…
- Trial name
- NCT04996810
- Testing
- PROTOXIN, Botox®
- Where
- 2 sites in South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Protox Inc.
Frown Lines, Glabellar Frown Lines
Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the CRYO-TOUCH III Device
myoscience Inc. (Redwood City, CA) has developed a device for a novel, minimally invasive facial rejuvenation procedure designed to soften hyperdynamic facial lines.
- Trial name
- NCT01808742
- Testing
- Treatment with CryoTouch III Device
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pacira Pharmaceuticals, Inc
Healthy
Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines
NT 201 is a Botulinum toxin type A preparation free of complexing proteins. Injected into the muscle, NT 201 causes a reversible local relaxation of the injected muscle.
- Trial name
- NCT00694148
- Testing
- NT 201
- Where
- Germany
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Merz Pharmaceuticals GmbH
Glabellar Frown Lines
AI-09 In Subjects With Glabellar Lines, GL-101
AI-09 In Subjects with Glabellar Lines
- Trial name
- NCT05565950
- Testing
- AI-09, Vehicle
- Where
- 4 sites in United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Eirion Therapeutics Inc.
Glabellar Frown Lines
Treatment of Moderate to Severe Glabellar Lines
The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe GL.
- Trial name
- READY-1 (NCT04249583)
- Testing
- botulinum toxin
- Where
- 14 sites in United States, Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Moderate-severe Glabellar Lines
Evaluation Onset Time of DWP450-004 and Safety in Moderate-severe Glabellar Lines
Evaluate onset time and safety of improvement effect of each group's forehead wrinkles after 2, 3, 4, 5, 14 days from administration of 20U dosage of DWP450-004 for adult patients who need more than moderate improvement of…
- Trial name
- NCT02568150
- Testing
- Single group, open-label
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Glabellar Frown Lines
Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines
Non-interventional PASS of NUCEIVA for the treatment of moderate-to-severe glabellar lines to provide additional characterisation of the long-term safety of NUCEIVA in the real-world clinical practice setting.
- Trial name
- NCT05481931
- Testing
- prabotulinumtoxinA
- Where
- Germany
- Volunteers
- 756 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Frown Lines
Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines
Efficacy and safety of ATGC-100 are assessed in subjects with moderate to severe glabellar lines.
- Trial name
- NCT04830345
- Testing
- ATGC-100 100U, Botox 100U
- Where
- South Korea
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
The primary objective is to demonstrate the safety of multiple doses of DWP-450 purified Botulinum neurotoxin, Type A, in treatment of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in…
- Trial name
- EV-006 (NCT02428608)
- Testing
- DWP-450 (Botulinum purified neurotoxin, Type A)
- Where
- United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Frown Lines
The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines
This study will be conducted in Phase Ⅲ clinical trials. In Phase Ⅲ, subjects with moderate to severe glabellar lines are enrolled and those who are judged to be eligible for this study will be injected with the "PROTOXIN" at a…
- Trial name
- NCT05364580
- Testing
- PROTOXIN, Botox®
- Where
- 5 sites in South Korea
- Volunteers
- 269 people, healthy volunteers welcome
- Sponsor
- Protox Inc.